Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II/III Double-Blind Placebo-Controlled Study of ME2125 (safinamide) in Parkinson's Disease with Wearing-Off
jRCT2080223002Phase 3Completed
- Sponsor
- Meiji Seika Pharma Co., Ltd.
- Start
- Nov 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of safinamide in Parkinson's disease (PD) (3 arms), sponsored by Meiji Seika Pharma Co., Ltd. Primary endpoints: Change in ON time and Motor function in ON phase. Started Nov 2015; status: completed.
02
Drugs
safinamide
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on jRCT2080223002.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080223002.